Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB198 in advanced solid malignancies
NCT06507306Phase 1Active, not recruiting
- Sponsor
- Kumquat Biosciences
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of KQB198 in solid tumor and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Kumquat Biosciences. Primary endpoints: Treatment-Emergent Adverse Events, Serious Adverse Events, and Dose-Limiting Toxicities at 28 days, Recommended Phase 2 Dose at 30 months and 1 more. Started Jun 2024; status: active, not recruiting.
02
Drugs
KQB198
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06507306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507306.